NeuBase Therapeutics, Inc. (NBSE)
Price:
0.38 USD
( - -0.01 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
NEWS
NeuBase Therapeutics Announces Receipt of Notice from Nasdaq
globenewswire.com
2024-04-05 16:05:00PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today reported that it received a notice (the “Notice) on April 4, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”) in a timely manner.
Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?
investorplace.com
2024-03-26 09:08:10NeuBase Therapeutics (NASDAQ: NBSE ) stock is falling on Tuesday after the company announced details for an upcoming special shareholder meeting. The big news here is that NeuBase Therapeutics is seeking shareholder approval for the liquidation and dissolution of the company.
Cheap Penny Stocks To Buy Now? 3 For Your Watch List
pennystocks.com
2023-09-14 12:00:29Penny stocks remain an alluring yet high-risk asset class for many novice investors. With share prices under $5, penny stocks appear affordable but bring higher volatility.
NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder
globenewswire.com
2023-09-08 07:00:00PITTSBURGH, Sept. 08, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today issued the following statement regarding the Schedule 13D filed with the U.S. Securities and Exchange Commission on August 31, 2023, by Symetryx Corporation (“Symetryx”) and their subsequent press release issued on September 6, 2023.
NeuBase (NBSE) Surges 107% on New Shareholder Acquiring Stake
zacks.com
2023-09-07 12:47:23With NeuBase (NBSE) exploring strategic alternatives to the company, Symetryx joins the company's shareholder base and urges the board to issue a unique $1 per share dividend.
Why Is NeuBase Therapeutics (NBSE) Stock Down 27% Today?
investorplace.com
2023-09-07 08:53:36NeuBase Therapeutics (NASDAQ: NBSE ) stock is dropping on Thursday but that's only due to the company coming off a massive rally yesterday. Investors will note that NBSE stock soared 107% higher on Wednesday after Symetryx announced a 20% stake in the company.
SYMETRYX CORPORATION ACQUIRES 20% STOCK IN NEUBASE
prnewswire.com
2023-09-06 10:00:00URGES BOARD TO CONSIDER A $1 DIVIDEND TORONTO , Sept. 6, 2023 /PRNewswire/ - Today, Symetryx Corporation ("Symetryx") announced that it has acquired 20% of the issued and outstanding common stock in Neubase Therapeutics Inc. (NASDAQ: NBSE) ("Neubase").
Why Is NeuBase Therapeutics (NBSE) Stock Up 19% Today?
investorplace.com
2023-09-06 08:04:33NeuBase Therapeutics (NASDAQ: NBSE ) stock is taking off on Wednesday despite a lack of news from the preclinical biopharmaceutical company. There are no new press releases from NeuBase Therapeutics or filings with the Securities and Exchange Commission (SEC) that explain why the stock is up today.
NeuBase Therapeutics to Explore Strategic Alternatives
globenewswire.com
2023-08-03 07:00:00PITTSBURGH, Aug. 03, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced that its Board of Directors (the “Board”) has completed a review of the Company's business, including the status of its programs, resources, and capabilities. The Board has made the determination to halt further development of the Company's programs and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value.
NeuBase Therapeutics Selected to Present Two Oral Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting
globenewswire.com
2023-05-02 17:00:00PITTSBURGH, May 02, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced two abstracts have been accepted for two oral presentations at the American Society of Gene & Cell Therapy (“ASGCT”) 26th Annual Meeting, which will take place in Los Angeles, CA and virtually on May 16-20, 2023.
What Makes NeuBase (NBSE) a New Strong Buy Stock
zacks.com
2023-01-20 13:32:31NeuBase (NBSE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for January 20th
zacks.com
2023-01-20 07:32:04NBSE, PRTG, RELL, HOWL and PATH have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2022.
Best Penny Stocks To Buy? 10 Under $1 To Watch This Week
pennystocks.com
2022-12-27 11:13:54Penny stocks to buy for under $1 but are they worth the risk? The post Best Penny Stocks To Buy?
Best Penny Stocks To Buy? 6 Under $1 To Watch Now
pennystocks.com
2022-12-23 12:45:52Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy?
NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce
zacks.com
2022-10-17 13:33:25NeuBase (NBSE) intends to reduce its existing workforce by nearly 60%. The company plans to maximize shareholder value and focus on the advancement of its platform in gene editing.
NeuBase (NBSE) Moves to Buy: Rationale Behind the Upgrade
zacks.com
2022-08-24 13:32:17NeuBase (NBSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
No data to display
NeuBase Therapeutics Announces Receipt of Notice from Nasdaq
globenewswire.com
2024-04-05 16:05:00PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today reported that it received a notice (the “Notice) on April 4, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”) in a timely manner.
Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?
investorplace.com
2024-03-26 09:08:10NeuBase Therapeutics (NASDAQ: NBSE ) stock is falling on Tuesday after the company announced details for an upcoming special shareholder meeting. The big news here is that NeuBase Therapeutics is seeking shareholder approval for the liquidation and dissolution of the company.
Cheap Penny Stocks To Buy Now? 3 For Your Watch List
pennystocks.com
2023-09-14 12:00:29Penny stocks remain an alluring yet high-risk asset class for many novice investors. With share prices under $5, penny stocks appear affordable but bring higher volatility.
NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder
globenewswire.com
2023-09-08 07:00:00PITTSBURGH, Sept. 08, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today issued the following statement regarding the Schedule 13D filed with the U.S. Securities and Exchange Commission on August 31, 2023, by Symetryx Corporation (“Symetryx”) and their subsequent press release issued on September 6, 2023.
NeuBase (NBSE) Surges 107% on New Shareholder Acquiring Stake
zacks.com
2023-09-07 12:47:23With NeuBase (NBSE) exploring strategic alternatives to the company, Symetryx joins the company's shareholder base and urges the board to issue a unique $1 per share dividend.
Why Is NeuBase Therapeutics (NBSE) Stock Down 27% Today?
investorplace.com
2023-09-07 08:53:36NeuBase Therapeutics (NASDAQ: NBSE ) stock is dropping on Thursday but that's only due to the company coming off a massive rally yesterday. Investors will note that NBSE stock soared 107% higher on Wednesday after Symetryx announced a 20% stake in the company.
SYMETRYX CORPORATION ACQUIRES 20% STOCK IN NEUBASE
prnewswire.com
2023-09-06 10:00:00URGES BOARD TO CONSIDER A $1 DIVIDEND TORONTO , Sept. 6, 2023 /PRNewswire/ - Today, Symetryx Corporation ("Symetryx") announced that it has acquired 20% of the issued and outstanding common stock in Neubase Therapeutics Inc. (NASDAQ: NBSE) ("Neubase").
Why Is NeuBase Therapeutics (NBSE) Stock Up 19% Today?
investorplace.com
2023-09-06 08:04:33NeuBase Therapeutics (NASDAQ: NBSE ) stock is taking off on Wednesday despite a lack of news from the preclinical biopharmaceutical company. There are no new press releases from NeuBase Therapeutics or filings with the Securities and Exchange Commission (SEC) that explain why the stock is up today.
NeuBase Therapeutics to Explore Strategic Alternatives
globenewswire.com
2023-08-03 07:00:00PITTSBURGH, Aug. 03, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced that its Board of Directors (the “Board”) has completed a review of the Company's business, including the status of its programs, resources, and capabilities. The Board has made the determination to halt further development of the Company's programs and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value.
NeuBase Therapeutics Selected to Present Two Oral Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting
globenewswire.com
2023-05-02 17:00:00PITTSBURGH, May 02, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced two abstracts have been accepted for two oral presentations at the American Society of Gene & Cell Therapy (“ASGCT”) 26th Annual Meeting, which will take place in Los Angeles, CA and virtually on May 16-20, 2023.
What Makes NeuBase (NBSE) a New Strong Buy Stock
zacks.com
2023-01-20 13:32:31NeuBase (NBSE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for January 20th
zacks.com
2023-01-20 07:32:04NBSE, PRTG, RELL, HOWL and PATH have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2022.
Best Penny Stocks To Buy? 10 Under $1 To Watch This Week
pennystocks.com
2022-12-27 11:13:54Penny stocks to buy for under $1 but are they worth the risk? The post Best Penny Stocks To Buy?
Best Penny Stocks To Buy? 6 Under $1 To Watch Now
pennystocks.com
2022-12-23 12:45:52Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy?
NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce
zacks.com
2022-10-17 13:33:25NeuBase (NBSE) intends to reduce its existing workforce by nearly 60%. The company plans to maximize shareholder value and focus on the advancement of its platform in gene editing.
NeuBase (NBSE) Moves to Buy: Rationale Behind the Upgrade
zacks.com
2022-08-24 13:32:17NeuBase (NBSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.